Extended Data Fig. 1: Characterization of ABPS cells.
From: Combined PD-1, BRAF and MEK inhibition in BRAFV600E colorectal cancer: a phase 2 trial
a, Spearman correlation (two-sided) of indicated immune signature levels at baseline and best percentage change from baseline in the size of target lesion from patients in clinical trial of dabrafenib/trametinib/panitumumab (DTP treatment arm only, n = 47). b, ABPS were treated with DT for 4, 24, 48, and 72 hours, and subjected to detection of phospho-RSK levels by WB (n = 3 independent biological experiments). c, APSe (APS cell line infected with retrovirus containing empty vector, used as control) and ABPS cells were treated with various doses of D, T, or DT for 72 hours, and subjected to cell viability assay (n = 3 independent biological experiments, data are presented as mean values +/− SEM). d, Individual growth curve of ABPS tumors across indicated treatment groups.
